Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15945MR)

This product GTTS-WQ15945MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ15945MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14367MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ8258MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ11743MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ2091MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ5421MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ7202MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ4925MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ10158MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LBR-101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW